| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Stine Smedegaard, Ulla Kampmann, Per G Ovesen, Henrik Støvring, Nikolaj Ritti. Whey Protein Premeal Lowers Postprandial Glucose Concentrations in Adults Compared with Water-The Effect of Timing, Dose, and Metabolic Status: a Systematic Review and Meta-analysis. The American journal of clinical nutrition. vol 118. issue 2. 2023-08-03. PMID:37536867. |
the underlying mechanisms are only partly understood but may involve stimulation of glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic polypeptide (gip), and insulin secretion together with a slower gastric emptying rate. |
2023-08-03 |
2023-08-14 |
Not clear |
| Eleonora Grespan, Andrea Mar. Does glucose lowering restore GIP effects on insulin secretion? - Reply to Sten Madsbad, Filip K Knop and Jens J Holst. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2023-07-24. PMID:37487785. |
does glucose lowering restore gip effects on insulin secretion? |
2023-07-24 |
2023-08-14 |
Not clear |
| Danielle L Jones, Clive J Petry, Keith Burling, Peter Barker, Elizabeth H Turner, Laura C Kusinski, Claire L Mee. Pregnancy glucagon-like peptide 1 predicts insulin but not glucose concentrations. Acta diabetologica. 2023-07-13. PMID:37439859. |
incretin hormones glucagon-like peptide 1 (glp-1) and gastric inhibitory peptide (gip) cause increased insulin secretion in non-pregnant adults, but their role in pregnancy, where there are additional metabolically-active hormones from the placenta, is less clear. |
2023-07-13 |
2023-08-14 |
Not clear |
| Michael A Nauck, Timo D Mülle. Incretin hormones and type 2 diabetes. Diabetologia. 2023-07-10. PMID:37430117. |
this appears to be because of a reduced ability of gip to stimulate insulin secretion, related either to an overall impairment of beta cell function or to specific defects in the gip signalling pathway. |
2023-07-10 |
2023-08-14 |
Not clear |
| Akira Mima, Atsuo Nomura, Takeshi Fuji. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-06-18. PMID:37331253. |
however, the insulin action after gip secretion is known to be drastically reduced in patients with type 2 diabetes. |
2023-06-18 |
2023-08-14 |
Not clear |
| Kimberley El, Jonathan D Douros, Francis S Willard, Aaron Novikoff, Ashot Sargsyan, Diego Perez-Tilve, David B Wainscott, Bin Yang, Alex Chen, Donald Wothe, Callum Coupland, Mattias H Tschöp, Brian Finan, David A D'Alessio, Kyle W Sloop, Timo D Müller, Jonathan E Campbel. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature metabolism. 2023-06-05. PMID:37277609. |
the incretins glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance |
2023-06-05 |
2023-08-14 |
human |
| Gaber El-Saber Batiha, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Nada A Ashour, Walaa A Neg. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach. Inflammopharmacology. 2023-05-19. PMID:37208555. |
the beneficial effect of tzt in t2dm and obesity is related to direct activation of gip and glp-1 receptors with subsequent improvement of insulin sensitivity and reduction of body weight. |
2023-05-19 |
2023-08-14 |
Not clear |
| Sten Madsbad, Filip K Knop, Jens J Hols. Does glucose lowering restore GIP's effect on insulin secretion? Nutrition, metabolism, and cardiovascular diseases : NMCD. 2023-05-07. PMID:37150733. |
does glucose lowering restore gip's effect on insulin secretion? |
2023-05-07 |
2023-08-14 |
Not clear |
| Daniel J Drucker, Jens J Hols. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023-03-28. PMID:36976349. |
incretin hormones, principally glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1(glp-1), potentiate meal-stimulated insulin secretion through direct (gip + glp-1) and indirect (glp-1) actions on islet β-cells. |
2023-03-28 |
2023-08-14 |
Not clear |
| Zhipeng Tao, Zhiyong Chen. Hormonal regulation of metabolism-recent lessons learned from insulin and estrogen. Clinical science (London, England : 1979). vol 137. issue 6. 2023-03-21. PMID:36942499. |
in addition, we discuss the cross-talk between estrogen signaling and insulin signaling via sirt1, mtor, and pi3k, as well as new therapeutic options such as agonists of glp1 receptor, gip receptor, and β3-ar. |
2023-03-21 |
2023-08-14 |
Not clear |
| Saiedeh Erfanian, Hamed Mir, Amir Abdoli, Abazar Roustazade. Association of gastric inhibitory polypeptide receptor (GIPR) gene polymorphism with type 2 diabetes mellitus in iranian patients. BMC medical genomics. vol 16. issue 1. 2023-03-07. PMID:36882778. |
gastric inhibitory polypeptide receptor (gipr) encodes a g-protein coupled receptor for gastric inhibitory polypeptide (gip), which was demonstrated to stimulate insulin secretion. |
2023-03-07 |
2023-08-14 |
Not clear |
| Bo Ahré. Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice. Biomedicines. vol 11. issue 2. 2023-02-25. PMID:36831127. |
contribution of gip and glp-1 to the insulin response to oral administration of glucose in female mice. |
2023-02-25 |
2023-08-14 |
mouse |
| Bo Ahré. Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice. Biomedicines. vol 11. issue 2. 2023-02-25. PMID:36831127. |
now, i have proceeded and studied the contribution of glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) to the insulin response to oral glucose in female mice by using receptor antagonists. |
2023-02-25 |
2023-08-14 |
mouse |
| Jarosław Nuszkiewicz, Jolanta Czuczejko, Wiktor Dróżdż, Alina Woźniak, Bogdan Małkowski, Karolina Szewczyk-Gole. Concentration of Selected Adipokines and Factors Regulating Carbohydrate Metabolism in Patients with Head and Neck Cancer in Respect to Their Body Mass Index. International journal of molecular sciences. vol 24. issue 4. 2023-02-25. PMID:36834693. |
the aim of the study was to determine the concentrations of ghrelin, omentin-1, adipsin, adiponectin, leptin, resistin, visfatin, glucagon, insulin, c-peptide, glucagon-like peptide-1 (glp-1), plasminogen activator inhibitor-1 (pai-1), and gastric inhibitory peptide (gip) in the blood serum of hnc patients depending on their body mass index (bmi). |
2023-02-25 |
2023-08-14 |
Not clear |
| Amy L George, Rachel E Foreman, Mariwan H Sayda, Frank Reimann, Fiona M Gribble, Richard G Ka. Rapid and Quantitative Enrichment of Peptides from Plasma for Mass Spectrometric Analysis. Methods in molecular biology (Clifton, N.J.). vol 2628. 2023-02-13. PMID:36781802. |
peptides studied using this methodology include insulin, c-peptide, glucagon, pyy, gip, and a number of other challenging gut peptide hormones. |
2023-02-13 |
2023-08-14 |
Not clear |
| Snehasish Nag, Samanwita Mandal, Tanmay Majumdar, Satinath Mukhopadhyay, Rakesh Kund. FFA-Fetuin-A regulates DPP-IV expression in pancreatic beta cells through TLR4-NFkB pathway. Biochemical and biophysical research communications. vol 647. 2023-01-30. PMID:36716646. |
dipeptidyl peptidase 4 (dpp-iv) is a ubiquitous proteolytic enzyme that cleaves incretin hormones, such as glucagon-like peptide 1 (glp1) and gastric inhibitory protein (gip), leading to reduced glucose stimulated insulin secretion from the pancreatic beta cells. |
2023-01-30 |
2023-08-14 |
mouse |
| Eleonora Grespan, Andrea Mar. Does glucose lowering restore GIP effects on insulin secretion? Nutrition, metabolism, and cardiovascular diseases : NMCD. 2023-01-29. PMID:36710118. |
does glucose lowering restore gip effects on insulin secretion? |
2023-01-29 |
2023-08-14 |
Not clear |
| Eleonora Grespan, Andrea Mar. Does glucose lowering restore GIP effects on insulin secretion? Nutrition, metabolism, and cardiovascular diseases : NMCD. 2023-01-29. PMID:36710118. |
some studies have shown that in type 2 diabetic patients the potentiation of insulin secretion by glucose-dependent insulinotropic polypeptide (gip) is compromised but can be partially restored if glucose is lowered. |
2023-01-29 |
2023-08-14 |
Not clear |
| Reema Abu Khalaf, Ebtisam Alwarafi, Dima Sabba. Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and Acta pharmaceutica (Zagreb, Croatia). vol 71. issue 4. 2023-01-18. PMID:36651550. |
dipeptidyl peptidase-iv (dpp-iv) inhibitors minimize glucagon and blood glucose levels by increasing the incretin levels, glucagon-like peptide (glp-1) and glucose-dependent insulinotropic poly-peptide (gip), leading to insulin secretion from pancreatic beta cells. |
2023-01-18 |
2023-08-14 |
Not clear |
| Giovanni Targher, Alessandro Mantovani, Christopher D Byrn. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. The lancet. Gastroenterology & hepatology. vol 8. issue 2. 2023-01-09. PMID:36620987. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretins that stimulate insulin secretion from pancreatic β cells in response to food ingestion. |
2023-01-09 |
2023-08-14 |
Not clear |